The new system helps expand office-based treatment options for non-melanoma skin cancer patients. Credit: Xstrahl.

Xstrahl has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiant Aura treatment system.

The new system has been developed to expand office-based treatment options for patients with non-melanoma skin cancer (NMSC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Radiant Aura is claimed to be the smallest office-based radiation therapy device currently available for dermatology practices.

The company worked with clinical users to develop the treatment solution, which provides an extended range of motion and one-handed manipulation.

It also facilitates easy manoeuvrability because of its re-engineered treatment arm, including a new telescopic treatment head.

See Also:

The patient set-up process is smooth, facilitated by a simple applicator and filter insertion and removal system. Its electromagnetic brakes help lock movements to improve patient safety.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the company is offering new 2.5cm, 5cm and 8cm applicators for more conformal radiation delivery.

Xstrahl CEO Adrian Treverton said: “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in order to give dermatologists multiple treatment options for their NMSC patients.

“Low-dose, X-ray-based therapy gives dermatology practices a non-invasive treatment option for patients when surgery is not possible, contraindicated or simply not preferred due to cosmetic concerns.

“Radiant Aura is the new generation of Radiant systems and has had multiple upgrades based on our early users’ experience and recommendations.”

Xstrahl is engaged in the design of radiation delivery devices for cancer researchers and clinical teams.